welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
status unknown
Ursodeoxycholic Acid in the Treatment of Duodenal Adenomas in Familial Adenomatous Polyposis (FAP) Patients
study id #: NCT00134758
condition: Adenomatous Polyposis Coli, Familial
status: status unknown
purpose:Malignant transformation of adenomas of the duodenum is now the leading cause of death in familial adenomatous polyposis (FAP) patients who had a restorative proctocolectomy. Ursodeoxycholic acid (UDCA) modifies the biliary acid profile and could reduce the severity of duodenal adenomas and prevent such transformation.
intervention:
Drug: Ursodeoxycholic acid
Drug: Placebo
study details
study contacts
expertly curated content related to this topic
-
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis PatientsThe purpose of this study is to determin...
-
Chemo: (Hair) Loss & Mane (Thinning)https://www.youtube.com/watch?v=TaGRE_J5...
-
Live Chat About the FAP 310 Clinical Trialhttps://www.youtube.com/watch?v=tKHUFgyO...
-
Cancer Prevention Pharmaceuticals (CPP) and Mallinckrodt Announce Results from Pivotal Phase 3 Trial of CPP-1X/Sulin...Cancer Prevention Pharmaceuticals, Inc.,...
-
Chemoprevention in Familial Adenomatous PolyposisFamilial adenomatous polyposis (FAP) pre...
-
Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatou...Exisulind (sulindac sulfone; FGN-1), a m...